1. SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP
- Author
-
Anne Bridgeman, Sushma Sharma, Peter Hillmen, Bernadeta Dadonaite, Jan Rehwinkel, Andrei Chabes, Jenny Klintman, Chiara Cursi, Tamara Davenne, Kim De Keersmaecker, Anna Schuh, Henry T.W. Blest, and Rachel E. Rigby
- Subjects
0301 basic medicine ,Male ,HIV-1 INFECTION ,Chronic lymphocytic leukemia ,Cell- och molekylärbiologi ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Cytotoxic T cell ,Deoxyguanosine ,heterocyclic compounds ,ANALOG INHIBITORS ,Cytotoxicity ,BCX-1777 ,AICARDI-GOUTIERES SYNDROME ,Deoxyguanosine triphosphate ,apoptosis ,Deoxyguanine Nucleotides ,dGTP ,Immucillin H ,Leukemia ,DEOXYGUANOSINE TOXICITY ,Female ,CyTOF ,Life Sciences & Biomedicine ,Intracellular ,Pyrimidinones ,PURINE NUCLEOSIDE PHOSPHORYLASE ,General Biochemistry, Genetics and Molecular Biology ,Article ,SAM Domain and HD Domain-Containing Protein 1 ,03 medical and health sciences ,Forodesine ,deoxyguanosine ,medicine ,Animals ,Humans ,DIFLUOROMETHYLENE PHOSPHONIC ACID ,PNP INHIBITOR ,Science & Technology ,CHRONIC LYMPHOCYTIC-LEUKEMIA ,Cell Biology ,Purine Nucleosides ,RESTRICTION FACTOR SAMHD1 ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,SAMHD1 ,dNTP ,IMMUCILLIN-H ,Mice, Inbred C57BL ,030104 developmental biology ,chemistry ,forodesine ,Drug Resistance, Neoplasm ,Cancer research ,chronic lymphocytic leukemia ,030217 neurology & neurosurgery ,Cell and Molecular Biology - Abstract
Summary The anti-leukemia agent forodesine causes cytotoxic overload of intracellular deoxyguanosine triphosphate (dGTP) but is efficacious only in a subset of patients. We report that SAMHD1, a phosphohydrolase degrading deoxyribonucleoside triphosphate (dNTP), protects cells against the effects of dNTP imbalances. SAMHD1-deficient cells induce intrinsic apoptosis upon provision of deoxyribonucleosides, particularly deoxyguanosine (dG). Moreover, dG and forodesine act synergistically to kill cells lacking SAMHD1. Using mass cytometry, we find that these compounds kill SAMHD1-deficient malignant cells in patients with chronic lymphocytic leukemia (CLL). Normal cells and CLL cells from patients without SAMHD1 mutation are unaffected. We therefore propose to use forodesine as a precision medicine for leukemia, stratifying patients by SAMHD1 genotype or expression., Graphical Abstract, Highlights • SAMHD1-deficient cells die upon exposure to deoxyguanosine (dG) • dG induces apoptosis in cells, including cancer cells, lacking SAMHD1 • PNP-inhibitors such as forodesine and dG synergistically trigger cell death • dG and forodesine kill mutated leukemic cells without SAMHD1 expression, SAMHD1 degrades deoxyribonucleoside triphosphates (dNTPs), the building blocks of DNA. Davenne et al. find that SAMHD1 protects cells against dNTP imbalances. Exposure of SAMHD1-deficient cells to deoxyguanosine (dG) results in increased intracellular dGTP levels and subsequent apoptosis. This can be exploited to selectively kill cancer cells that acquired SAMHD1 mutations.
- Published
- 2019